Patents by Inventor Michal Abraham

Michal Abraham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide therapy for increasing platelet levels
    Patent number: 9427456
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.
    Type: Grant
    Filed: June 13, 2010
    Date of Patent: August 30, 2016
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Michal Abraham, Amnon Peled, Orly Eizenberg
  • METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION
    Publication number: 20160243187
    Abstract: There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.
    Type: Application
    Filed: October 30, 2014
    Publication date: August 25, 2016
    Inventors: Amnon PELED, Michal ABRAHAM
  • T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy
    Patent number: 8765683
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Grant
    Filed: January 29, 2012
    Date of Patent: July 1, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER
    Publication number: 20140154249
    Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 5, 2014
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Michal ABRAHAM, Orly Eizenberg, Amnon Peled
  • Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
    Patent number: 8685398
    Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: April 1, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Michal Abraham, Orly Eizenberg, Amnon Peled
  • T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
    Patent number: 8663651
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: March 4, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • METHODS FOR OBTAINING A THERAPEUTICALLY EFFECTIVE AMOUNT OF HEMATOPOIETIC PRECURSOR CELLS AND LONG TERM ENGRAFTMENT THEREOF
    Publication number: 20140030211
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Application
    Filed: May 8, 2013
    Publication date: January 30, 2014
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon PELED, Michal Begin, Katia Beider, Michal Abraham
  • Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
    Patent number: 8455450
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: June 4, 2013
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY
    Publication number: 20120207748
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Application
    Filed: January 29, 2012
    Publication date: August 16, 2012
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS
    Publication number: 20120094907
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.
    Type: Application
    Filed: June 13, 2010
    Publication date: April 19, 2012
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Michal Abraham, Amnon Peled, Orly Einzenberg
  • NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER
    Publication number: 20120087921
    Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.
    Type: Application
    Filed: June 15, 2010
    Publication date: April 12, 2012
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Michal Abraham, Orly Eizenberg, Amnon Peled
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY
    Publication number: 20100184694
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Application
    Filed: December 23, 2007
    Publication date: July 22, 2010
    Applicant: BIOKINE THERAPEUTICS LTD.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY
    Publication number: 20100166715
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Application
    Filed: December 23, 2007
    Publication date: July 1, 2010
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION
    Publication number: 20100143334
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
    Type: Application
    Filed: December 23, 2007
    Publication date: June 10, 2010
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham